David Williams BSc, GDipResMeth
Chief Executive Officer
David Williams is a University of Melbourne clinical toxinologist and herpetologist working on improving the treatment of snakebite in Papua New Guinea (PNG). He conducted clinical studies of the management of snakebite in PNG as a PNG Department of Health/University of PNG affiliated researcher while undertaking his PhD with the assistance of a Nossal Institute for Global Health/Australian Venom Research Unit scholarship. David has worked on snakebite projects for the World Health Organization in Cambodia and in Geneva, including the drafting of WHO’s Guidelines for the Production, Control and Regulation of Snake Antivenom Immunoglobulins, and the production of the WHO’s venomous snake distribution and antivenoms database. In Cambodia he conducted an evaluation of snakebite management issues for the WHO’s Western Pacific Regional Office and the Cambodian Ministry of Health. Together with Dr Simon Jensen, he has developed practical snakebite management training courses for doctors and healthworkers in Papua New Guinea and Cambodia. David was the senior editor and an author of PNG’s first textbook on envenoming, Venomous bites and stings in Papua New Guinea, published in 2005. He collaborates with a number of international colleagues on issues relating to improving snakebite treatment, venomous snake systematics, venom proteomics and antivenom development.
Professor, Dr David A. Warrell MA, DM, DSc, FRCP, FRCPE, FMedSci
David Warrell is International Director (Hans Sloane Fellow) of the Royal College of Physicians of London; Emeritus Professor of Tropical Medicine and Honorary Fellow of St Cross College, University of Oxford; Principal Fellow, Australian Venom Research Unit, University of Melbourne; and Honorary Professor at universities in Peru and China. After training in Oxford and London, he has lived and worked; as physician, teacher, researcher, traveller and naturalist; in many tropical countries, founding the Oxford Tropical Medicine Research Network in Thailand in 1979. His interests include infectious, tropical and respiratory diseases, venomous animals, envenoming, and expedition medicine. Currently, he is consultant to the World Health Organization, British Army and Foreign and Commonwealth Office, Royal Geographical Society and Earthwatch International and Conservation Fellow of the Zoological Society of London. He was formerly head of the Nuffield Department of Clinical Medicine in Oxford and president of the International Federation for Tropical Medicine and the Royal Society of Tropical Medicine and Hygiene. He is senior editor of the Oxford Textbook of Medicine (5th Edition, April 2010), Essential Malariology and the Oxford Handbook of Expedition and Wilderness Medicine and author of papers on malaria, rabies, relapsing fevers and other tropical infectious diseases, HIV, respiratory diseases and clinical toxinology.
Dr Simon Jensen BSc(Hons), MSc(Dist.), MBChB, FACEM
Simon Jensen is an emergency physician and clinical toxinologist at a major regional Australian hospital, and holds honorary appointments as a Research Fellow at the Australian Venom Research Unit at the University of Melbourne, as Lecturer in Emergency Medicine at the School of Medicine & Health Sciences at the University of Papua New Guinea, and Emergency Consultant at Port Moresby General Hospital. In addition to his interests in envenoming, he teaches on a number of specialist training courses, and is interested in travel and expedition medicine. Simon is a full member of the International Society on Toxinology (IST) and is involved in various Australasian toxinology research projects. He was spent time working in Papua New Guinea for over a decade, and since 2004 has been the clinical director of the AVRU-UPNG Snakebite Research Project, and the is a founding member of the Charles Campbell Toxinology Centre at the University of PNG. He is a World Health Organisation (WHO) consultant in snakebite management education to Cambodia. With David Williams, he developed the snakebite management training courses for doctors and healthworkers that run in Papua New Guinea and Cambodia, and he was an editor and an author of PNG’s first textbook on envenoming, Venomous bites and stings in Papua New Guinea. He is also co-author of numerous papers, conference presentations & teaching presentations on snakebite.
Dr José María Gutiérrez BSc, PhD.
José María Gutiérrez has a B.Sc. in Microbiology and a PhD in Physiological Sciences. He works at Instituto Clodomiro Picado, University of Costa Rica, where he performs research relating to a number of aspects of snake venom toxinology, improvements to antivenom production and preclinical evaluation, and the pathophysiology of envenoming. He has been involved in the development of new antivenoms for several regions of the world outside of Costa Rica, including Latin America, West Africa, Papua New Guinea and Sri Lanka. He is a WHO consultant on antivenom production and the problems of envenoming, and was involved with the drafting of WHO’s Guidelines for the Production, Control and Regulation of Snake Antivenom Immunoglobulins. In addition, he teaches Immunology, Cellular Pathology and Research Methods at the Universidad de Costa Rica in San José.
Dr Nick Brown BSc, MBBS, GCSpMed, (UQ) MPhil (Cantab)
Nick Brown is a medical graduate from the University of Queensland currently working at the Royal Brisbane and Women’s Hospital. He has undertaken postgraduate qualifications in Radiology and Bioscience Enterprise in Australia and at Cambridge, where he completed his thesis on snake antivenom in sub-Saharan Africa. This included an analysis of the cost-effectiveness of snake antivenom and the market drivers influencing the industry. He is also a research fellow at the Australian Venom Research Unit. Ongoing research projects include diagnostic and therapeutic radiolabelled compounds, including antivenoms, as well as healthcare economics, sports medicine and infectious diseases. Nick works as a part-time consultant Medical Director for MicroPharm Ltd., helping to increase the quantity and quality of antivenom in Africa, as well as improve therapeutic options for other “orphan” disease areas.